Brief: AB Science Receives New Authorisations For masitinib Study
14/09/2021 17:31
Sept 14 (Reuters) - AB SCIENCE SA ABS.PA :
* AB SCIENCE ANNOUNCED THAT IT HAS RECEIVED NEW
AUTHORIZATIONS TO
RESUME PATIENT ENROLLMENT IN ITS PHASE 3 STUDIES OF MASITINIB
Source text for Eikon: ID:nGNX7tB5lb
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041